Free Trial

Edap Tms (NASDAQ:EDAP) Earns Sell (E+) Rating from Weiss Ratings

Edap Tms logo with Medical background

Key Points

  • Edap Tms (NASDAQ:EDAP) has received a reaffirmed "sell (E+)" rating from Weiss Ratings, indicating analysts' lack of confidence in the stock's performance.
  • The company's stock traded at $2.21 with a market capitalization of $82.63 million, reflecting a 52-week range between $1.21 and $3.08.
  • Over 62.74% of Edap Tms stock is owned by hedge funds and institutional investors, suggesting significant institutional interest despite the negative rating.
  • Five stocks we like better than EDAP TMS.

Edap Tms (NASDAQ:EDAP - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Edap Tms Stock Performance

Shares of EDAP traded up $0.01 during mid-day trading on Wednesday, reaching $2.21. 11,277 shares of the company's stock were exchanged, compared to its average volume of 45,920. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.51 and a quick ratio of 1.05. The stock has a market capitalization of $82.63 million, a PE ratio of -3.62 and a beta of -0.15. The business's fifty day simple moving average is $2.00 and its 200-day simple moving average is $1.83. Edap Tms has a 52-week low of $1.21 and a 52-week high of $3.08.

Hedge Funds Weigh In On Edap Tms

A number of hedge funds have recently modified their holdings of the business. Cetera Investment Advisers grew its position in shares of Edap Tms by 33.9% during the first quarter. Cetera Investment Advisers now owns 75,000 shares of the medical equipment provider's stock worth $147,000 after acquiring an additional 19,000 shares during the last quarter. Simplicity Wealth LLC purchased a new position in Edap Tms in the 2nd quarter valued at $54,000. Millennium Management LLC grew its position in Edap Tms by 218.5% in the 4th quarter. Millennium Management LLC now owns 48,915 shares of the medical equipment provider's stock valued at $108,000 after buying an additional 33,558 shares during the last quarter. Sage Mountain Advisors LLC purchased a new position in Edap Tms in the 2nd quarter valued at $165,000. Finally, Scoggin Management LP purchased a new position in Edap Tms in the 1st quarter valued at $686,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

About Edap Tms

(Get Free Report)

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in EDAP TMS Right Now?

Before you consider EDAP TMS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EDAP TMS wasn't on the list.

While EDAP TMS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.